| Company Name | Bayer |
|---|---|
| Protocol Number | 18981 |
| Title of Study | XAMINA / Xarelto® on prevention of stroke and non-central nervous system systeMIc embolism in treatment Naïve Asian patients with non-valvular atrial fibrillation. |
| Primary Objective | The primary objective is to assess the safety of rivaroxaban regarding the rate of major bleeding in treatment naïve NVAF patients under clinical practice conditions. |
| Number of Sites | 10 |
| Period of Study | From：September 2017 to：September 2019 |
| Number of Patients | 200人 |
| IRB Approval Date | NTUH: 06/22/2017 NCKUH: 07/12/2017 CMUH: 07/13/2017 CCH: 07/29/2017 MMH: 07/31/2017 CMMC: 08/01/2017 VGHTC: 08/04/2017 KMUH: 08/10/2017 VGHTPE: 08/10/2017 CHGH: 09/16/2017 |
| Publication Plan / Date | September 2020 |
